1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.66%
Cash & equivalents yoy growth at least 1.5x the Drug Manufacturers - Specialty & Generic median of 0.87%. Joel Greenblatt might see strong liquidity accumulation as an advantage. Check if management invests or just hoards cash.
No Data
No Data available this quarter, please select a different quarter.
2.66%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
0.05%
Receivables growth is below half the Drug Manufacturers - Specialty & Generic median of 4.90% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
47.19%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.90%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
11.61%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
10.71%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 2.10%. Joel Greenblatt sees a potential liquidity edge if well allocated.
3.89%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -0.09%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
-0.80%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-1.38%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.10%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-1.01%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of -0.42%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-10.68%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-50.22%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
0.20%
Below half the Drug Manufacturers - Specialty & Generic median of -0.64%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
3.70%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.20%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
16.13%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 2.08%. Jim Chanos might see a warning sign of stressed supplier payments.
52.83%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
31.04%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-1.71%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
No Data
No Data available this quarter, please select a different quarter.
15.82%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 3.38%. Jim Chanos suspects potential working capital strain.
-5.81%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
-7210156610258723.00%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential shortage of multi-year commitments.
4.01%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
1859068900.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-4.44%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.15%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-0.23%
Below half Drug Manufacturers - Specialty & Generic median of 0.81%. Joel Greenblatt sees a much lower liability expansion vs. peers.
5.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
33.47%
Below half Drug Manufacturers - Specialty & Generic median of -0.35%. Jim Chanos suspects poor profitability or large dividend drains.
-33.57%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-3727.08%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
5.49%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.30%. Joel Greenblatt sees stronger equity growth vs. peers.
3.70%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.20%. Joel Greenblatt sees more aggressive expansions than peers.
-10.68%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-4.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-481.95%
Above 1.5x Drug Manufacturers - Specialty & Generic median -0.02%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
